Clinical Trials

Inclusion Criteria:

• Age ≥ 18 years.
• Diagnosis of AML, HR-MDS, or high marrow blast MDS/MPN (including CMML).
• Prior treatment history must include 1-4 prior lines of therapy.
• Adequate organ function evidenced by the following laboratory values:
  • Creatinine clearance (CL) ≥ 60 mL/min;
  • Total serum bilirubin < 1.5 × upper limit of normal (ULN);
  • Alanine aminotransferase (ALT) ;
  • Aspartate aminotransferase(AST) < 2.5 × ULN;
  • White blood cell count at the time of the first dose < 10 k/µL.
• Eastern Cooperative Oncology Group performance status ≤ 2.
• Female patients of childbearing potential must have a negative pregnancy test within 7 days before study treatment initiation and if sexually active, agree to use a highly effective form of contraception throughout their participation during study treatment and up to 4 months after the last dose of study drug
• Male patients with female partners of childbearing potential must, even if surgically sterilized, agree to practice effective barrier contraception during the entire study treatment period and through four months after the last dose of study drug, or practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant.

Exclusion Criteria:

• Diagnosis of acute promyelocytic leukemia.
• Isolated extramedullary relapse (phase 2 only).
• Active central nervous system (CNS) leukemia.
• History of other malignancy.
• Any of the following cardiopulmonary abnormalities:
  • Myocardial infarction within six months prior to registration;
  • New York Heart Association Class III or IV heart failure or known left ventricular ejection fraction < 50%;
  • A history of familial long QT syndrome;
  • Symptomatic atrial or ventricular arrhythmias not controlled by medications;
  • QTcF ≥ 470 msec calculated according to institutional guidelines, unless due to underlying bundle branch block and/or pacemaker and with approval of the medical monitor;
  • Known moderate to severe and clinically significant chronic obstructive pulmonary disease, interstitial lung disease and/or pulmonary fibrosis (e.g., requiring home oxygen therapy).
• Pregnancy and/or lactation.
• Major surgery (excluding placement of vascular access) within 4 weeks prior to first dose of CTX-712.
• History of allogeneic organ transplantation (excluding cornea).
• History of allogenic hematopoietic stem cell transplantation within 6 months of planned study treatment initiation and/or graft-versus host disease grade ≥ 1 following allogenic hematopoietic stem cell transplantation.
• History of or chimeric antigen receptor T-cell therapy or other modified T cell therapy.
• Active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus, hepatitis C virus, known human immunodeficiency virus, or acquired immunodeficiency syndrome related illness. Infections controlled with oral anti-infective agents, including prophylactic treatments, are allowed. Patient must be viral load negative.
• Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.
• Concomitant use of strong CYP3A4 inhibitors (Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers | FDA) within 5 half-lives of the drug of interest prior to the initiation of study treatment, or consumption of St John’s wort, grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit, within 3 days prior to the initiation of study treatment. Use of azole antifungals that are not strong CYP3A4 inhibitors (e.g., isavuconazole or fluconazole) is permitted.
  • Note: Concomitant use of azole antifungals will be evaluated in separate cohorts after RP2D determination.
• Concomitant use of breast cancer resistance protein (BCRP) inhibitors and proton pump inhibitors (PPIs), within 7 days prior to the initiation of study treatment.
  • Note: Concomitant use of PPI will be evaluated in separate cohorts after RP2D determination.

Eligibility last updated 12/12/23. Questions regarding updates should be directed to the study team contact.